Abstract

Autosomal recessive whole gene deletions of nephrocystin-1 (NPHP1) result in abnormal structure and function of the primary cilia. These deletions can result in a tubulointerstitial kidney disease known as nephronophthisis and retinal (Senior–Løken syndrome) and neurological (Joubert syndrome) diseases. Nephronophthisis is a common cause of end-stage kidney disease (ESKD) in children and up to 1% of adult onset ESKD. Single nucleotide variants (SNVs) and small insertions and deletions (Indels) have been less well characterised. We used a gene pathogenicity scoring system (GenePy) and a genotype-to-phenotype approach on individuals recruited to the UK Genomics England (GEL) 100,000 Genomes Project (100kGP) (n = 78,050). This approach identified all participants with NPHP1-related diseases reported by NHS Genomics Medical Centres and an additional eight participants. Extreme NPHP1 gene scores, often underpinned by clear recessive inheritance, were observed in patients from diverse recruitment categories, including cancer, suggesting the possibility of a more widespread disease than previously appreciated. In total, ten participants had homozygous CNV deletions with eight homozygous or compound heterozygous with SNVs. Our data also reveals strong in-silico evidence that approximately 44% of NPHP1 related disease may be due to SNVs with AlphaFold structural modelling evidence for a significant impact on protein structure. This study suggests historical under-reporting of SNVS in NPHP1 related diseases compared with CNVs.

Details

Title
A genotype-to-phenotype approach suggests under-reporting of single nucleotide variants in nephrocystin-1 (NPHP1) related disease (UK 100,000 Genomes Project)
Author
Leggatt, Gary 1 ; Cheng, Guo 2 ; Narain, Sumit 2 ; Briseño-Roa, Luis 3 ; Annereau, Jean-Philippe 3 ; Ambrose, J. C. 4 ; Arumugam, P. 4   VIAFID ORCID Logo  ; Bevers, R. 4 ; Bleda, M. 4   VIAFID ORCID Logo  ; Boardman-Pretty, F. 5   VIAFID ORCID Logo  ; Boustred, C. R. 4 ; Brittain, H. 4   VIAFID ORCID Logo  ; Brown, M. A. 4 ; Caulfield, M. J. 5 ; Chan, G. C. 4 ; Giess, A. 4   VIAFID ORCID Logo  ; Griffin, J. N. 6   VIAFID ORCID Logo  ; Hamblin, A. 4 ; Henderson, S. 5 ; Hubbard, T. J. P. 4   VIAFID ORCID Logo  ; Jackson, R. 4   VIAFID ORCID Logo  ; Jones, L. J. 5 ; Kasperaviciute, D. 5 ; Kayikci, M. 4   VIAFID ORCID Logo  ; Kousathanas, A. 4   VIAFID ORCID Logo  ; Lahnstein, L. 4 ; Lakey, A. 4 ; Leigh, S. E. A. 4   VIAFID ORCID Logo  ; Leong, I. U. S. 4   VIAFID ORCID Logo  ; Lopez, F. J. 4 ; Maleady-Crowe, F. 4 ; McEntagart, M. 4   VIAFID ORCID Logo  ; Minneci, F. 4 ; Mitchell, J. 4 ; Moutsianas, L. 5   VIAFID ORCID Logo  ; Mueller, M. 5   VIAFID ORCID Logo  ; Murugaesu, N. 4 ; Need, A. C. 5   VIAFID ORCID Logo  ; O‘Donovan, P. 4   VIAFID ORCID Logo  ; Odhams, C. A. 4   VIAFID ORCID Logo  ; Patch, C. 5   VIAFID ORCID Logo  ; Perez-Gil, D. 4 ; Pereira, M. B. 4   VIAFID ORCID Logo  ; Pullinger, J. 4   VIAFID ORCID Logo  ; Rahim, T. 4   VIAFID ORCID Logo  ; Rendon, A. 4   VIAFID ORCID Logo  ; Rogers, T. 4 ; Savage, K. 4 ; Sawant, K. 4 ; Scott, R. H. 4 ; Siddiq, A. 4   VIAFID ORCID Logo  ; Sieghart, A. 4   VIAFID ORCID Logo  ; Smith, S. C. 4   VIAFID ORCID Logo  ; Sosinsky, A. 5   VIAFID ORCID Logo  ; Stuckey, A. 4   VIAFID ORCID Logo  ; Tanguy, M. 4   VIAFID ORCID Logo  ; Tavares, A. L. Taylor 4 ; Thomas, E. R. A. 5   VIAFID ORCID Logo  ; Thompson, S. R. 4   VIAFID ORCID Logo  ; Tucci, A. 5   VIAFID ORCID Logo  ; Welland, M. J. 4 ; Williams, E. 4   VIAFID ORCID Logo  ; Witkowska, K. 5 ; Wood, S. M. 5 ; Zarowiecki, M. 4   VIAFID ORCID Logo  ; Gast, Christine 7 ; Gilbert, Rodney D. 8 ; Ennis, Sarah 2 

 University of Southampton, Duthie Building (MP 808), Southampton General Hospital, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297); Portsmouth Hospitals University NHS Trust, Wessex Kidney Centre, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761); University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, UK (GRID:grid.123047.3) (ISNI:0000000103590315) 
 University of Southampton, Duthie Building (MP 808), Southampton General Hospital, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297) 
 Imagine Institute for Genetic Diseases, Medetia, Paris, France (GRID:grid.462336.6) 
 Genomics England, London, UK (GRID:grid.498322.6) 
 Genomics England, London, UK (GRID:grid.498322.6); Queen Mary University of London, William Harvey Research Institute, London, UK (GRID:grid.4868.2) (ISNI:0000 0001 2171 1133) 
 University of East Anglia, Norwich, UK (GRID:grid.8273.e) (ISNI:0000 0001 1092 7967) 
 University of Southampton, Duthie Building (MP 808), Southampton General Hospital, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297); Portsmouth Hospitals University NHS Trust, Wessex Kidney Centre, Portsmouth, UK (GRID:grid.418709.3) (ISNI:0000 0004 0456 1761) 
 University of Southampton, Duthie Building (MP 808), Southampton General Hospital, Southampton, UK (GRID:grid.5491.9) (ISNI:0000 0004 1936 9297); Southampton General Hospital, Southampton Children’s Hospital, Southampton, UK (GRID:grid.123047.3) (ISNI:0000000103590315) 
Pages
9369
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2825556633
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.